Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Cancer|July 13, 2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemiaStefan Faderl, Kanti Rai, John Gribben, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2019
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response ProteinsRashmi Gupta, Wentian Li, Xiao J Yan, et al.Nature Reviews. Disease Primers|January 20, 2017
Chronic lymphocytic leukaemiaThomas J Kipps, Freda K Stevenson, Catherine J Wu, et al.Leukemia & Lymphoma|April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.Blood|October 24, 2002
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)John C Byrd, Bercedis L Peterson, Vicki A Morrison, et al.Molecular Medicine (Cambridge, Mass.)|March 24, 2007
Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemiaFabio Ghiotto, Franco Fais, Emilia Albesiano, et al.Blood|May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011John C Byrd, Kanti Rai, Bercedis L Peterson, et al.Clinical Lymphoma|April 10, 2004
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemiaMichael Keating, Stephen Coutré, Kanti Rai, et al.Leukemia Research|May 27, 2005
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activityIan W Flinn, John C Byrd, Nancy Bartlett, et al.Blood|October 15, 2005
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemiaJacques-Louis Binet, Federico Caligaris-Cappio, Daniel Catovsky, et al.Pageof 4